Uğur KÜÇÜK, Bahadır KIRILMAZ, Ertuğrul ERCAN

Koroner Stent Uygulanan ST Elevasyonsuz Miyokard İnfarktüsünde Pentraksin-3’ün Uzun Vadeli Prognostik Önemi

Amaç: ST elevasyonu olmayan miyokard infarktüsü (NSTEMI) ve stabil anjina pektoris (SAP) tanısıyla perkütan koroner girişim (PKG) yapılmış hastalarda ardışık ölçülen pentraksin-3 (PTX3) düzeylerinin Gensini risk skoru ve uzun dönem takiplerde kardiyovasküler mortalite ile ilişkisini araştırmayı amaçladık. Gereç ve Yöntem: Çalışmamız retrospektif olarak planlanmış olup PKG yapılan NSTEMI ve SAP tanılı hastaların uzun dönem kardiyovasküler mortalite sonuçları değerlendirildi. Çalışmamız, çalışma ve kontrol grubu olmak üzere iki gruptan oluşmaktadır. PKG yapılan NSTEMI tanılı 18 hasta çalışma grubuna, SAP tanılı 37 hasta ise kontrol gurubuna dahil edildi. Tüm hastalardan başvuru anı, 8. ve 24. saatte PTX3 ölçümleri için kan örnekleri alındı. Gensini skorları PKG öncesi hesaplandı. Bulgular: Sekizinci saatte bakılan PTX3 düzeyleri NSTEMI hastalarında SAP tanılı hastalara göre sayısal ve istatistiksel olarak anlamlı saptandı [13,37 (5,47-27,75) ve 5 (3,83-12,42), p=0,006]. Başvuru anında bakılan PTX3 değerleri Gensini skoru ile ilişkili saptandı (r=0,299, p=0,026). Sekizinci saatte bakılan PTX3 değerleri uzun dönem kardiyovasküler mortalite için bağımsız öngördürücü olarak saptandı (Hazard oranı: 1,294, %95 güven aralığı: 1,024-1,653, p=0,039). Sonuç: PTX3, NSTEMI hastalarında uzun dönemde kardiyovasküler mortalite için yüksek riskli bireylerin belirlenmesinde yardımcı olabilir.

Long-term Prognostic Significance of Pentraxin-3 in Patients with Non-ST Elevation Myocardial Infarction and Coronary Stenting

Aim: We aimed to investigate the relationship of serially measured pentraxin-3 (PTX3) levels with Gensini risk score and cardiovascular mortality in long-term follow-up in patients who underwent percutaneous coronary intervention (PCI) with the diagnosis of non-ST elevation myocardial infarction (NSTEMI) and stable angina pectoris (SAP). Materials and Methods: Our study was planned retrospectively, and the long-term cardiovascular mortality results of patients with NSTEMI and SAP, who underwent PCI, were evaluated. Our study consisted of two groups, including the study and the control groups. Eighteen patients with NSTEMI who underwent PCI were included in the study group, and 37 patients with a diagnosis of SAP were included in the control group. Blood samples were taken from all patients for PTX3 measurements at the time of admission, at the 8th and 24th hours. Gensini scores were calculated before PCI. Results: PTX3 levels measured at the eighth hour were found to be numerically and statistically significant in NSTEMI patients compared to SAP patients [13.37 (5.47-27.75) and 5 (3.83-12.42), p=0.006]. PTX3 values measured at the time of admission were found to be associated with Gensini score (r=0.299, p=0.026). PTX3 values measured at the eighth hour were found to be independent predictors of long-term cardiovascular mortality (Hazard ratio: 1.294, 95% confidence interval: 1024-1.653, p=0.039). Conclusion: PTX3 may be helpful in identifying individuals at high risk for cardiovascular mortality in the long term in NSTEMI patients.

PDF

___

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139-e596.
2. Fox KA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J. 2000;21:1440-9.
3. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213-20.
4. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006;18:10-5.
5. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:e10-4.
6. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636-41.
7. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161-7.
8. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
9. Sinning C, Lillpopp L, Appelbaum S, Ojeda F, Zeller T, Schnabel R, et al. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol. 2013;102:495-503.
10. Chen ZW, Chen YH, Qian JY, Ma JY, Ge JB. Validation of a novel clinical prediction score for severe coronary artery diseases before elective coronary angiography. PLoS One. 2014;9:e94493.
11. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932-6.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:e1-121.
13. Karamfilova V, Assyov Y, Nedeva I, Gateva A, Ivanova I, Cherkezov N, et al. Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord. 2022;20:132-6.
14. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48-55.
15. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636-41.
16. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349-54.
17. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
18. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-9.
19. Landry A, Docherty P, Ouellette S, Cartier LJ. Causes and outcomes of markedly elevated C-reactive protein levels. Can Fam Physician. 2017;63:e316-23.
20. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699-708.
21. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636-41.
22. Ustündağ M, Orak M, Güloğlu C, Sayhan MB, Alyan O, Kale E. Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol Derg. 2011;11:588-94.
23. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48-55.
24. Kurup R, Patel S. Neutrophils In Acute Coronary Syndrome. EMJ Cardiol. 2017;5:79-87.
25. Akgul O, Baycan OF, Bulut U, Somuncu MU, Pusuroglu H, Ozyilmaz S, et al. Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26:592-7.
26. Altay S, Çakmak HA, Kemaloğlu Öz T, Özpamuk Karadeniz F, Türer A, Erer HB, et al. Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study. Anatol J Cardiol. 2017;17:202-9.
27. Terkelsen CJ, Lassen JF, Nørgaard BL, Gerdes JC, Jensen T, Gøtzsche LB, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J. 2005;26:18-26.